The company has long been committed to the modernization and internationalization of traditional Chinese medicines, and has continuously upgraded the technical connotation of traditional Chinese medicines by applying new processes, new dosage forms, and new auxiliary materials of modern drug research, and has formed the "large-scale application of extraction and refining technology represented by membrane separation and countercurrent extraction", "quality control technology of traditional Chinese medicines represented by fingerprinting", and "quality control technology of traditional Chinese medicines represented by fingerprinting". The company has formed such leading technical features as "application scale of extraction and refining technology represented by membrane separation and counter-current extraction", "modernization of quality control technology of traditional Chinese medicine represented by fingerprinting", "serialization of new dosage forms of traditional Chinese medicine led by injections and soft gelatin capsules", and established the leading position of the technology in the domestic traditional Chinese medicine industry. It has also formed core competitive advantages in the fields of Chinese medicine gynecology, pediatrics, orthopedics, antitumor, cardiovascular and cerebrovascular.
As of 2006, the company has independently researched and developed 35 new drugs at national level, of which 2 are Class II, 8 are Class III, and 25 are Class IV. The company has undertaken 3 scientific research projects under the national "863" program, 2 demonstration projects for high-technology industrialization under the State Planning Commission, 2 major special projects of the State Economy and Trade Commission, and 11 national Spark and Torch Programs, and has declared 114 domestic and foreign patents, with the number of invention patents granted ranking the highest among domestic enterprises. The number of authorized invention patents ranks the 8th among domestic enterprises. The company has successfully developed more than ten soft capsule series of new drugs, such as Liufei Di Huang Soft Capsule, and the soft capsule preparation technology has reached the leading level in China; the self-developed Heat Toxin Ning Injection and Pain An Injection are the representative varieties under the guidance of the latest national standard of injection authentication; the company's leading product, Gui Zhi Por Capsules, has been approved to carry out the second phase of the monitoring bed test in the United States. The company's leading product, Gui Zhi Fu capsule, has been approved to undergo Phase II trial in the US.
The company has strong research and development strength. The company has a strong R & D strength. The R & D center has seven departments: Preparation Research Institute, Pharmaceutical and Chemical Research Institute, Pharmacology Research Institute, Process Technology Research Institute, Clinical Research Department, Information and Approval Department, and Detection and Analysis Department. With a laboratory area of 10,000m2 and experimental equipments worth 50 million RMB, the company has a scientific and technological development team consisting of more than 130 scientific and technological personnel with bachelor's degree or above, including 11 PhDs, 12 masters and 8 senior engineers. It is capable of engaging in the construction of information system, prescription screening, pharmacological screening, process research, quality standard research, pilot scale-up research, clinical research, and the whole process of drug research for approval and registration. The company and the Chinese Academy of Sciences, Shanghai Institute of Organic Chemistry, Peking University, China Pharmaceutical University, Nanjing University of Traditional Chinese Medicine and other top scientific research institutes in China to establish a natural drug laboratory, biochemical drug laboratory, Jiangsu Zhongkang drug science and technology development company, such as 8 *** built laboratories, the existing research varieties are mainly involved in the anti-tumor, anti-infective, cardio-cerebral and cerebral vascular therapeutic areas. 2002 the company's R & D center has been identified as In 2002, the company's R&D center has been recognized as "National Postdoctoral Research Station" and "National Enterprise Technology Center".
The company's modernized traditional Chinese medicine production base, with a factory area of 85,000 square meters and a comprehensive preparation workshop of 58,000 square meters, possesses thirteen advanced production lines for capsules, oral liquids, traditional Chinese medicine injections, tablets, punches, small-volume injections, lyophilized powdered needles, tinctures and other products that have passed the state's GMP validation as well as the supporting preparation center, quality inspection center, power center and management center, and is equipped with the capability of producing 1.2 billion hard capsules, oral liquids, and tincture annually. It has the annual production capacity of 1.2 billion hard capsules, 100 million oral liquids, 170 million soft capsules, 30 million injections, 1.5 billion tablets and 1,000 tons of granules. Production base of Chinese medicine pretreatment workshop, the use of domestic and foreign advanced extraction of Chinese herbal medicines and pre-treatment technology, means, equipped with monitoring systems and online cleaning facilities, to achieve the extraction of Chinese medicine pipeline, functional, can produce various types of Chinese medicine extracts or Chinese medicine mono-particle, etc., with an annual processing, extraction of 10,000 tons of production capacity of the Chinese herbal medicines, the industry in the country in a leading position.
The company has a professional marketing team of more than 1,500 people, divided into gynecological line, orthopedic line, anti-infective line, retail and C terminal four segments, in 28 provinces and cities across the country, with 31 sales branches, 131 sales offices, with more than 800 pharmaceutical businessmen across the country to establish a long-term and stable business relationship, the product coverage of nearly 5,000 more than the county-level medical units. The company has the right of self-managed export, part of the products are exported to Japan, South Korea, Southeast Asia and other countries and regions, in Hong Kong, Canada, Australia, with distribution centers, branches.
Production base